新华制药：关于获得磷酸奥司他韦干混悬剂药品注册证书的公告

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Suspension from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1 - The company announced the approval of Oseltamivir Phosphate Suspension, which is a key product in its portfolio [1] - The registration certificate signifies compliance with national drug regulations, enhancing the company's market position [1] - This approval may lead to increased sales and market share in the antiviral medication segment [1]